SCHEMBL3434732

SCHEMBL3434732

CCNC(=O)Nc1cc(-c2nc(C)c(C(=O)NC3CCCCC3)s2)c(-c2cncc(C(=O)OC)c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
POLQ O75417 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432773 0.99 POLQ (0.38) LMNAPOLQ
SCHEMBL3432770 0.96 POLQ (0.40) POLQ
SCHEMBL3433226 0.93 PPARD (0.40) LMNA
SCHEMBL3434775 0.92 PPARA (0.40)
SCHEMBL1505477 0.91
SCHEMBL1505604 0.90
SCHEMBL3434766 0.89 NPC1 (0.38) POLQ
SCHEMBL3434740 0.87 ABL1 (0.39)
SCHEMBL1505473 0.87
SCHEMBL3431844 0.85 LMNA (0.36) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101100-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 ASTRAZENECA AB (SE) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101100-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 UROD, UMPS, SLC14A1 LMNA 2441/4885POLQ 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.